Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia

被引：16

作者：

Bhavnani, Sujata M. ^{[1
]}

Forrest, Alan ^{[1
]}

Hammel, Jeffrey P. ^{[1
]}

Drusano, George L. ^{[2
]}

Rubino, Christopher M. ^{[1
]}

Ambrose, Paul G. ^{[1
]}

机构：

[1] Ordway Res Inst, Inst Clin Pharmacodynam, Albany, NY 12206 USA

[2] Ordway Res Inst, Emerging Infect & Pharmacodynam Lab, Albany, NY 12206 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2008年 / 62卷 / 01期

关键词：

quinolones; Streptococcus pneumoniae; community-acquired pneumonia;

D O I：

10.1016/j.diagmicrobio.2008.04.008

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Exposure-response analyses were performed using data from 89 patients (10 clinical trials) with Streptococcus pneumoniae community-acquired pneumonia who received quinolones. Relationships between the free-drug AUC/MIC ratio and clinical and microbiologic response were identified. Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：99 / 101

页数：3

共 12 条

[1] Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis [J].

Ambrose, PG ;

Anon, JB ;

Owen, JS ;

Van Wart, S ;

McPhee, ME ;

Bhavnani, SM ;

Piedmonte, M ;

Jones, RN .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (11) :1513-1520

[2] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].

Ambrose, PG ;

Grasela, DM ;

Grasela, TH ;

Passarell, J ;

Mayer, HB ;

Pierce, PF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797

[3] COMMUNITY-ACQUIRED PNEUMONIA [J].

BARTLETT, JG ;

MUNDY, LM .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1618-1624

[4]

BELLO A, 2001, 41 INT C ANT AG CHEM

[5] Gemifloxacin for the treatment of respiratory tract infections: In vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety [J].

Bhavnani, SM ;

Andes, DR .

PHARMACOTHERAPY, 2005, 25 (05) :717-740

[6]

CRAIG WA, 2000, 40 INT C ANT AG CHEM

[7] Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males [J].

Efthymiopoulos, C ;

Bramer, SL ;

Maroli, A .

CLINICAL PHARMACOKINETICS, 1997, 33 (Suppl 1) :1-8

[8] Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis [J].

Forrest, A ;

Chodosh, S ;

Amantea, MA ;

Collins, DA ;

Schentag, JJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 :45-57

[9] PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].

FORREST, A ;

NIX, DE ;

BALLOW, CH ;

GOSS, TF ;

BIRMINGHAM, MC ;

SCHENTAG, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081

[10] Review of treatment guidelines for community-acquired pneumonia [J].

Niederman, MS .

AMERICAN JOURNAL OF MEDICINE, 2004, 117 :51-57

← 1 2 →